CAS |
No.101626-70-4 |
中文名称 |
他利克索 |
英文名称 |
Talipexole |
别名 |
B-HT920 |
分子式 |
C10H15N3S |
分子量 |
209.31 |
溶解性 |
Soluble in DMSO(Need ultrasonic) |
纯度 |
≥98% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
SMILES |
C=CCN1CCC2=C(CC1)SC(=N2)N |
InChIKey |
DHSSDEDRBUKTQY-UHFFFAOYSA-N |
InChI |
InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12) |
PubChem CID |
5374 |
靶点 |
Dopamine Receptor |
通路 |
Neuronal Signaling;GPCR & G Protein |
背景说明 |
是一种多巴胺激动剂,可用于帕金森综合症的相关研究。 |
生物活性 |
Talipexole 是一种多巴胺激动剂,被用作抗帕金森病药物。[1-2] |
In Vivo |
Talipexole exerts dopamine-agonistic actions in stimulating locomotor activity and alpha 1-adrenergic actions in inducing salivation and enhanced loss of body weight.[1] Concomitant treatment with talipexole inhibited MPTP-induced autolysis and individual death in a concentration-dependent manner. Post-treatment with talipexole at 1 hr after MPTP completely inhibited MPTP-induced individual death.[2] |
数据来源文献 |
[1]. Van der Laan JW. Dopaminergic and alpha 1-adrenergic properties of B-HT920 revealed in morphine-dependent rats. Pharmacol Biochem Behav. 1987 Feb;26(2):265-9. [2]. Kitamura Y,et al. Protective effect of talipexole on MPTP-treated planarian,a unique parkinsonian worm model. Jpn J Pharmacol. 1998 Sep;78(1):23-9. |
规格 |
5mg |
单位 |
瓶 |